At $900–$1,400 per month list price, branded GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound are among the most expensive chronic medications in American healthcare. Only an estimated 10–25% of commercially insured patients have meaningful GLP-1 coverage for weight loss, and Medicare Part D was prohibited from covering weight-loss medications until very recently. This guide covers every financial strategy available to make GLP-1 therapy accessible and sustainable across income levels and insurance situations nationwide.
Multiple prescription discount mechanisms can significantly reduce out-of-pocket GLP-1 costs for uninsured and underinsured patients. Understanding which tools apply to your specific insurance situation can mean the difference between $1,400/month and $99/month — a distinction that determines whether GLP-1 therapy is sustainable long-term.
GLP-1 medication costs depend on insurance status: commercially insured patients may qualify for manufacturer savings programs ($25–$150/month copay cap); uninsured patients can use GoodRx, RxSaver, or compounding pharmacies ($200–$500/month); Medicaid patients in states with obesity coverage may pay $0; Medicare patients are newly eligible for Wegovy for cardiovascular risk reduction. Understanding your category is the essential first step in minimizing costs.
GoodRx and RxSaver provide instant prescription discount coupons that can reduce GLP-1 costs at major pharmacy chains — CVS, Walgreens, Rite Aid, Walmart, Kroger, and thousands of independent pharmacies nationwide. For cash-paying patients, GoodRx can reduce Ozempic from $900+ to $700–$800/month — meaningful but still expensive. However, for smaller doses or medications available as generic (metformin, older GLP-1 options), GoodRx can produce dramatic savings. Available through the GoodRx app in all 50 states.
No Enrollment RequiredNovo Nordisk (maker of Ozempic and Wegovy) offers the Novo Nordisk Patient Assistance Program (NNPAP) for patients without insurance who meet income eligibility criteria (typically under 400% of federal poverty level). Qualifying patients receive free medications directly from the manufacturer. The application process requires proof of income and insurance status. Patient advocacy services can assist with applications — available to eligible patients in all 50 states through primary care providers and obesity medicine practices.
Free MedicationNovo Nordisk's Wegovy Savings Card reduces copays to as low as $0–$25/month for eligible commercially insured patients whose insurance covers Wegovy for chronic weight management. Eligibility requires commercial insurance (not Medicaid or Medicare) and prior authorization approval. The savings card can be used at any retail pharmacy in the United States. Annual benefit limits apply — typically saving patients $200–$1,200 per month compared to full copay. Enrollment available online or through prescribing physicians nationwide.
Commercial InsuranceMark Cuban's Cost Plus Drugs has announced plans to offer GLP-1 medications at dramatically reduced margins compared to traditional pharmacy pricing. Combined with emerging biosimilar semaglutide products expected to reach the U.S. market, the GLP-1 pricing landscape is expected to shift significantly in coming years. Monitoring alternative pharmacy models — particularly for patients currently on compounded semaglutide — will become increasingly important as the market evolves. Cost Plus serves patients nationwide through mail-order pharmacy service.
Emerging OptionHealth Savings Accounts (HSA) and Flexible Spending Accounts (FSA) offer pre-tax dollar savings on GLP-1 medications — effectively a 22–37% discount depending on income tax bracket. For patients with employer-sponsored high-deductible health plans, maximizing HSA contributions specifically to fund GLP-1 costs is a sophisticated tax strategy growing in popularity among the health-focused GLP-1 demographic.
GLP-1 medications prescribed for a medical condition (Type 2 diabetes, obesity) are eligible HSA expenses — meaning patients can pay for them with pre-tax dollars. The 2026 HSA contribution limit is $4,300 for individuals and $8,550 for families. For a patient in the 24% tax bracket paying $300/month for compounded semaglutide, using HSA funds saves over $860 annually. HSA providers including Fidelity HSA, Lively, and HealthEquity offer investment options for long-term account growth. Available to any employee with a qualifying high-deductible health plan nationwide.
Pre-Tax SavingsEmployer-sponsored FSAs allow pre-tax contributions for GLP-1 medications, lab testing, dietitian services, glucose monitors, and other GLP-1-related medical expenses. The 2026 FSA limit is $3,200. Unlike HSAs, FSAs typically have "use-it-or-lose-it" rules — making careful annual planning important. HR departments at major employers in New York, Chicago, San Francisco, Dallas, and other business centers are increasingly providing GLP-1 financial guidance as part of their employee benefits communications.
Employer BenefitMedical credit cards including CareCredit and Alphaeon Credit offer 0% promotional financing for 6–24 months on GLP-1 medications, lab testing, cosmetic procedures, and related services. For patients who need GLP-1 medications immediately but face cash flow constraints, medical credit provides bridge financing — particularly useful for the initial months before insurance approval comes through. CareCredit is accepted at thousands of healthcare providers, pharmacies, and medical spas nationwide.
Financing OptionIndependent health insurance brokers who specialize in GLP-1-inclusive plan selection help patients find commercial insurance plans with the best GLP-1 coverage during Open Enrollment periods. These brokers — particularly in major markets like New York, Los Angeles, Chicago, Houston, and Miami — can identify formulary placement, prior authorization requirements, and copay structures across multiple insurance carriers to maximize GLP-1 accessibility. Self-employed and individual market purchasers benefit most from this specialized guidance.
Expert NavigationCanadian provincial drug plans offer varying GLP-1 coverage: Ontario's ODB program and BC PharmaCare have established criteria for semaglutide coverage in diabetes, while Alberta Blue Cross covers GLP-1s for eligible beneficiaries — providing a useful contrast to U.S. patchwork coverage. In the UK, the NHS has published prescribing criteria for Wegovy (semaglutide 2.4mg) through specialist weight management services, while European reimbursement systems in Germany, the Netherlands, France, and Spain are each developing their own coverage frameworks as the clinical evidence base grows.
GLP-1 insurance coverage varies significantly by state Medicaid programs. States with obesity medication Medicaid coverage include California, Illinois, and Louisiana. States actively considering expansion include New York, Massachusetts, Washington, Colorado, and Minnesota. Medicare now covers Wegovy for patients with established cardiovascular disease following the SELECT trial results. Internationally, Canadian provincial drug plans (Ontario ODB, BC PharmaCare, Alberta Blue Cross), the UK NHS, and emerging European reimbursement frameworks in Germany, the Netherlands, Scandinavia, Spain, and France are all shaping global GLP-1 access policy.